Have questions or want to find out more?
How orthotopic models supported by MRI improve your preclinical studies outcome
Subcutaneous models are widely used for the evaluation of new drug candidates. However, they lack the native tumor microenvironment, leading to limited reproducibility of the complexity of human cancers. To address this, orthotopic models have emerged as an alternative, enabling evaluation of tumor progression, invasion, and therapeutic response in a setting closer to clinical reality. Supported by advanced imaging methods such as MRI, they open the way to more translationable preclinical studies.
In this webinar, our experts will introduce the principles and advantages of orthotopic models in oncology research, highlighting how they better capture the biology of human tumors with the assistance of imaging. We will demonstrate how MRI allows non-invasive, longitudinal monitoring of orthotopic tumor growth and treatment response, offering unique insights that cannot be achieved by conventional methods.
Through practical case studies, we will demonstrate how the integration of MRI imaging in your preclinical studies make orthotopic models powerful tools for your drug development programs, while abiding to the 3Rs rule.
View this webinar to discover how this powerful combination can improve the predictivity of your oncology programs and accelerate the path from preclinical research to clinical impact
Damien France
Study & Research Director
Damien studied Biology at the IUT de Lyon before pursuing advanced training at the École Pratique des Hautes Études. He joined Oncodesign Services in 1997 as an in vivo technician, where he built strong expertise in pharmacology and preclinical models. Over the years, he progressively took on broader responsibilities, first as in vivo engineer, then as laboratory manager in immunohistochemistry, in vivo and animal facility.
Since 2017, Damien has been working as a Preclinical Study Director, overseeing a wide range of translational oncology programs. He recently joined the Pharmaco-Imaging team, where he applies his experience in in vivo pharmacology to the design and management of imaging studies. His long-standing knowledge of preclinical models and histopathology strengthens the integration of imaging approaches into drug discovery and development programs.
Peggy Provent
Head of study & research unit, Pharmaco-Imaging
Peggy Provent obtained a PhD in 2006 in Physics from the University of Grenoble, France, where she mainly worked on the development of novel MRI technics to characterize brain tumors in preclinical models.
Peggy joined Oncodesign Services in 2008 as a study director in the Pharmaco-Imaging Unit. She has been participating in the development of the preclinical imaging platform. As a physicist, she supervises all our imaging equipment, data management and image analysis with the goal of always improving the throughput and the quality of our pharmacology studies.